Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A information to most cancers immunotherapy: from T cell primary science to scientific observe. Nat. Rev. Immunol. 20, 651–668 (2020).
Google Scholar
Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies—BiTEs and past. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).
Google Scholar
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in continual lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
Google Scholar
Sharma, P. & Allison, J. P. The way forward for immune checkpoint remedy. Science 348, 56–61 (2015).
Google Scholar
Bhoj, V. G. et al. Persistence of long-lived plasma cells and humoral immunity in people responding to CD19-directed CAR T-cell remedy. Blood 128, 360–370 (2016).
Google Scholar
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Google Scholar
Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Pure innate and adaptive immunity to most cancers. Annu. Rev. Immunol. 29, 235–271 (2011).
Google Scholar
Trabolsi, A., Arumov, A. & Schatz, J. H. T cell-activating bispecific antibodies in most cancers remedy. J. Immunol. 203, 585–592 (2019).
Google Scholar
Wu, L. et al. Trispecific antibodies improve the therapeutic efficacy of tumor-directed T cells by T cell receptor co-stimulation. Nat. Most cancers 1, 86–98 (2020).
Google Scholar
Steinmetz, A. et al. CODV-Ig, a common bispecific tetravalent and multifunctional immunoglobulin format for medical functions. MAbs 8, 867–878 (2016).
Google Scholar
Berchuck, A. et al. Overexpression of HER-2/neu is related to poor survival in superior epithelial ovarian most cancers. Most cancers Res. 50, 4087–4091 (1990).
Google Scholar
Burstein, H. J. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353, 1652–1654 (2005).
Google Scholar
Gravalos, C. & Jimeno, A. HER2 in gastric most cancers: a brand new prognostic issue and a novel therapeutic goal. Ann. Oncol. 19, 1523–1529 (2008).
Google Scholar
Kim, E. Okay., Kim, Okay. A., Lee, C. Y. & Shim, H. S. The frequency and scientific impression of HER2 alterations in lung adenocarcinoma. PLoS ONE 12, e0171280 (2017).
Google Scholar
Pollock, N. I. & Grandis, J. R. HER2 as a therapeutic goal in head and neck squamous cell carcinoma. Clin. Most cancers Res. 21, 526–533 (2015).
Google Scholar
Santin, A. D. et al. Amplification of c-erbB2 oncogene: a significant prognostic indicator in uterine serous papillary carcinoma. Most cancers 104, 1391–1397 (2005).
Google Scholar
Siena, S. et al. Focusing on the human epidermal progress issue receptor 2 (HER2) oncogene in colorectal most cancers. Ann. Oncol. 29, 1108–1119 (2018).
Google Scholar
Slamon, D. J. et al. Human breast most cancers: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Google Scholar
Yoon, H. H. et al. Affiliation of HER2/ErbB2 expression and gene amplification with pathologic options and prognosis in esophageal adenocarcinomas. Clin. Most cancers Res. 18, 546–554 (2012).
Google Scholar
Hicks, D. G. & Kulkarni, S. HER2+ breast most cancers: assessment of biologic relevance and optimum use of diagnostic instruments. Am. J. Clin. Pathol. 129, 263–273 (2008).
Google Scholar
Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to trastuzumab in breast most cancers. Clin. Most cancers Res. 15, 7479–7491 (2009).
Google Scholar
Shak, S. Overview of the trastuzumab (herceptin) anti-HER2 monoclonal antibody scientific program in HER2-overexpressing metastatic breast most cancers. Herceptin Multinational Investigator Research Group. Semin. Oncol. 26, 71–77 (1999).
Google Scholar
Wang, J. & Xu, B. Focused therapeutic choices and future views for HER2-positive breast most cancers. Sign Transduct. Goal Ther. 4, 34 (2019).
Google Scholar
Laux, I. et al. Response variations between human CD4(+) and CD8(+) T-cells throughout CD28 costimulation: implications for immune cell-based therapies and research associated to the enlargement of double-positive T-cells throughout getting older. Clin. Immunol. 96, 187–197 (2000).
Google Scholar
Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and administration. Blood 127, 3321–3330 (2016).
Google Scholar
Kroschinsky, F. et al. New medication, new toxicities: extreme unwanted side effects of recent focused and immunotherapy of most cancers and their administration. Crit. Care 21, 89 (2017).
Google Scholar
Saber, H., Del Valle, P., Ricks, T. Okay. & Leighton, J. Okay. An FDA oncology evaluation of CD3 bispecific constructs and first-in-human dose choice. Regul. Toxicol. Pharmacol. 90, 144–152 (2017).
Google Scholar
Baselga, J. et al. Section II research of weekly intravenous trastuzumab (herceptin) in sufferers with HER2/neu-overexpressing metastatic breast most cancers. Semin. Oncol. 26, 78–83 (1999).
Google Scholar
Zuch de Zafra, C. L. et al. Focusing on a number of myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine launch. Clin. Most cancers Res. 25, 3921–3933 (2019).
Google Scholar
Harbeck, N. et al. HER2 dimerization inhibitor pertuzumab—mode of motion and scientific information in breast most cancers. Breast Care (Basel) 8, 49–55 (2013).
Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the therapy of HER2+ metastatic breast most cancers. Curr. Opin. Mol. Ther. 12, 350–360 (2010).
Google Scholar
Bang, Y. J. et al. First-in-human part 1 research of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in sufferers with HER2-positive superior strong tumors. Ann. Oncol. 28, 855–861 (2017).
Google Scholar
Jones, Okay. L. & Buzdar, A. U. Evolving novel anti-HER2 methods. Lancet Oncol. 10, 1179–1187 (2009).
Google Scholar
Mignot, F. et al. Concurrent administration of anti-HER2 remedy and radiotherapy: systematic assessment. Radiother. Oncol. 124, 190–199 (2017).
Google Scholar
Vu, T. & Claret, F. X. Trastuzumab: up to date mechanisms of motion and resistance in breast most cancers. Entrance. Oncol. 2, 62 (2012).
Google Scholar
Buie, L. W., Pecoraro, J. J., Horvat, T. Z. & Daley, R. J. Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann. Pharmacother. 49, 1057–1067 (2015).
Google Scholar
Tran, B. et al. 609O Outcomes from a part I research of AMG 160, a half-life prolonged (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune remedy for metastatic castration-resistant prostate most cancers (mCRPC). Ann. Oncol. 31, s507 (2020).
Deegen, P. et al. The PSMA-targeting half-life prolonged BiTE remedy AMG 160 has potent antitumor exercise in preclinical fashions of metastatic castration-resistant prostate most cancers. Clin. Most cancers Res. 27, 2928–2937 (2021).
Google Scholar
Raghu, G. et al. SAR156597 in idiopathic pulmonary fibrosis: a part 2 placebo-controlled research (DRI11772). Eur. Respir. J. 52, 1801130 (2018).
Google Scholar
Service provider, A. M. et al. An environment friendly path to human bispecific IgG. Nat. Biotechnol. 16, 677–681 (1998).
Google Scholar
Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV safety in macaques. Science 358, 85–90 (2017).
Google Scholar
Alegre, M. L. et al. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57, 1537–1543 (1994).
Google Scholar
Smith, Okay. B. & Ellis, S. A. Standardisation of a process for quantifying floor antigens by oblique immunofluorescence. J. Immunol. Strategies 228, 29–36 (1999).
Google Scholar